The microbial metabolome: remodeling the therapeutic landscape in hematologic malignancies
Gut bacteria produce metabolites that influence how blood cancer patients respond to chemotherapy and immunotherapy, opening new avenues for microbiome-based treatment optimization.
This review explores how gut microbiome-derived metabolites modulate outcomes in hematologic malignancies, affecting chemotherapy efficacy, immunotherapy response, and transplant results. The authors propose a translational pathway from metabolome association studies toward microbiome-targeted interventions as an adjunct to precision oncology in blood cancers.
What the study was
- Study design
- Review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- NPJ Biofilms and Microbiomes
Why it surfaced
Relevant review synthesizing emerging microbiome-oncology connection in hematologic malignancies; increasing research interest in this area; review design limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.